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Abstract
A case–control study was conducted to identify risk factors for
Pneumocystis jirovecii pneumonia (PCP) in renal transplant recipi-
ents. Eleven cases of PCP were matched with 22 controls.
Cases occurred a median of 18 months after transplantation,
and none of the recipients was receiving prophylaxis. Univari-
ate analysis showed that graft rejection, duration of steroid
use, use of mammalian target of rapamycin (mTOR) inhibitors
and lymphocytopenia at the time of prophylaxis discontinuation
were risk factors for PCP. In the multivariate model, only graft
rejection (OR 8.66, p 0.017) remained signiﬁcantly associated
with PCP. In patients with a history of graft rejection, PCP
prophylaxis should be maintained, especially among those with
lymphocytopenia.
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Several recent studies have described clusters of renal
transplant recipients diagnosed with Pneumocystis jirovecii
pneumonia (PCP) several months after transplantation and
prophylaxis discontinuation [1–8]. A history of graft rejec-
tion has been identiﬁed as a potential risk factor in several
studies, and the role of immunosuppressive regimens has
also been debated [4–8]. Interpatient transmission of P. ji-
rovecii or prophylaxis failure was suspected in some studies
[9,11].
Following the occurrence of consecutive cases of PCP
among renal transplant recipients in our centre, we decided
to perform a retrospective case–control study to identify
risk factors associated with PCP. The study was performed
in a single renal transplant unit in Paris, where PCP prophy-
laxis with cotrimoxazole (480 mg once daily) is started after
transplantation for a ﬁxed duration of 3 months.
Cases were deﬁned by the identiﬁcation in bronchoalveo-
lar lavage ﬂuid or in induced sputum of P. jirovecii
trophozoites or cysts (by Giemsa staining and/or immunoﬂu-
orescence) or detection of P. jirovecii DNA by PCR in cases
with clinical and radiological features consistent with PCP
and no other plausible diagnosis. Using our computerized
database, each case was matched with two controls without
PCP at the date of renal transplantation; cases and controls
therefore had similar durations of follow-up. Univariate and
multivariate analyses were then performed, using exact con-
ditional logistic regression, in order to identify risk factors
associated with PCP. Associations of variables with PCP
were expressed in terms of exact ORs with their 95% CIs.
Reported p-values are mid-p-values that adjusted for the dis-
creteness of the distribution. All tests were two-sided, and
p-values of <0.05 were taken to indicate statistical signiﬁ-
cance. Analyses were performed using SAS 9.1 software
(SAS Institute Inc., Cary, NC, USA).
From January 2006 to June 2007, 11 cases of PCP were
diagnosed among 11 patients who underwent renal transplan-
tation between June 1992 and February 2006. During this per-
iod, 750 patients underwent renal transplantation in our
centre. The characteristics and outcome of PCP cases are
reported in Table 1. All cases occurred late after PCP prophy-
laxis withdrawal, a median of 18 months after renal transplan-
tation. All required hospital admission and presented with the
usual features of PCP. It is of note that ﬁve patients (45%) pre-
sented with acute respiratory failure. The outcome was satis-
factory after patients received high-dose cotrimoxazole
therapy, except for two patients, one of whom died. This
unusually low mortality rate might be related to the small sam-
ple size of our study or to the early diagnosis of PCP in our
institution, which has a great deal of experience in PCP
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diagnosis and treatment, and where many human immunodeﬁ-
ciency virus-infected patients are taken care of.
In the case–control study, a number of variables were
associated with the risk of PCP in the univariate analysis
(Table 2). Indeed, and similar to what has been reported
previously, a history of graft rejection was one of the stron-
gest predictors of PCP, with an OR of 14.4 (95% CI 2.1–inf,
p 0.002) [4,5,7]. Also, the use of mTOR inhibitors (OR 7.7,
95% CI 1.2–inf, p 0.02) and a longer duration of high-dose
steroid use (OR 1.6 per month, 95% CI: 1.04–2.93, p 0.005)
were both associated with a higher risk of PCP. Cases were,
however, less likely than controls to have received calcineu-
rin inhibitors (OR 0.09, 95% CI 0–0.67, p 0.004). Finally, a
low lymphocyte count (<500/lL) at the time of prophylaxis
discontinuation was associated with a higher risk of PCP
(OR 18.1, 95% CI 1.66–inf, p 0.0027). We could not assess
CD4 T-cell counts in this study, as they were not routinely
measured in our patients.
Given the low number of cases in this study, and because
variables associated with the risk of PCP in the univariate
model were likely to be colinear with rejection, we tested,
in a multivariate model, whether a low lymphocyte count
(<500/lL) at the time of prophylaxis discontinuation
remained associated with PCP when graft rejection was
selected as the main variable. In this model, only graft rejec-
tion (OR 8.66, p 0.017) remained signiﬁcantly associated with
PCP, whereas a low lymphocyte count was no longer signiﬁ-
cantly associated with the risk of PCP, although a trend was
seen (OR 5.84, p 0.083) (Table 2). Indeed, a low CD4 T-cell
count has previously been suggested to be a very reliable
risk factor for PCP in patients with and without human
immunodeﬁciency virus infection [11–13]. In renal transplant
recipients, as monitoring of CD4 T-cell counts is not rou-
tinely performed, total lymphocyte count could be a good
surrogate marker and a proxy of immunosuppression result-
ing from use of steroids and immunosuppressive agents. It is
also a simple and convenient marker to measure. Owing to
the small sample size in our study, however, and on the basis
of the experience of a single institution, it may not be possi-
ble to generalize our ﬁndings to other renal transplant cen-
tres, and further studies need to be conducted, in particular
to conﬁrm the role of lymphocytopenia.
Despite its limitations, our study therefore suggests that
among patients with graft rejection, PCP prophylaxis should
be maintained or resumed, especially in patients with low
lymphocyte counts (<500/lL). Indeed, all cases of PCP in our
study were reported among patients in whom PCP prophy-
laxis had been discontinued. PCP prophylaxis has been very
successful in almost eliminating the risk of PCP among renal
transplant recipients during the ﬁrst 3 months after trans-
plantation. PCP prophylaxis usually relies on the use of a low
daily dose of cotrimoxazole. Renal intolerance is unusual
when such a low dose of cotrimoxazole is used, even in
renal transplant recipients, and is fully reversible upon treat-
ment discontinuation. In cases of sulfonamide intolerance,
oral atovaquone (750 mg twice daily) appears to be a simple
and safe alternative, with a low risk of drug–drug interactions
and no renal toxicity [1].
In conclusion, among renal transplant recipients, PCP can
still occur several months after transplantation, late after
prophylaxis discontinuation. Graft rejection appears to be
the major risk factor for PCP in these patients. PCP prophy-
laxis should therefore be maintained or resumed, especially
when lymphocytopenia is present, as it could further
increase the risk of PCP.
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TABLE 1. Characteristics and outcome of 11 cases of Pneu-
mocystis jirovecii pneumonia (PCP) among renal transplant
recipients
Cases n = 11
Median age, years (range) 53 (28–73)
Male sex, n (%) 7 (64)




Proportion of patients still under
prophylaxis at PCP diagnosis, n (%)
0 (0)
Clinical presentation
Cough, n (%) 11 (100)
Fever, n (%) 11 (100)
Dyspnoea, n (%) 8 (73)
Acute respiratory failure, n (%) 5 (45)
Lymphocyte count at prophylaxis
discontinuation, median (Q1–Q3)/lL
430 (348–688)
Lymphocyte count at PCP diagnosis, median (Q1–Q3)/lL 440 (380–540)
PCP diagnosis, n (%)
P. jirovecii cysts in BAL ﬂuid or induced sputum 10 (91)
P. jirovecii DNA detected by PCR in induced sputumb 1 (9)
Post-transplant CMV viraemia, n (%) 8 (73)
Bacterial co-infection at PCP diagnosis, n (%) 4 (36)
Pulmonaryc 3 (27)
Bacteraemia (Listeria monocytogenes) 1 (9)
Radiological ﬁndings on chest X-ray or CT scan, n (%)
Bilateral alveolar or interstitial inﬁltrates 11 (100)
Fibrosis 1 (9)
Treatment
Cotrimoxazole, n (%) 11 (100)
Outcome, n (%)
Cure 9 (81)
Chronic respiratory failure 1 (9)
Death 1 (9)
BAL, bronchoalveolar lavage; CMV, cytomegalovirus; CT, computed tomography.
a(Q1–Q3): interquartile range.
bThis patient had clinical and radiological manifestations consistent with PCP,
and there was no alternative diagnosis. He could not undergo BAL, because of
respiratory failure. He fully recovered after PCP treatment.
cBAL cultures were positive for Streptococcus pneumoniae in one patient, for
Staphylococcus aureus and Pseudomonas aeruginosa in one patient, and for P. aeru-
ginosa in one patient.
1376 Clinical Microbiology and Infection, Volume 16 Number 9, September 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1375–1381
References
1. Fishman JA. Prevention of infection caused by Pneumocystis carinii in
transplant recipients. Clin Infect Dis 2001; 33: 1397–1405.
2. Di Cocco P, Orlando G, Bonanni L et al. A systematic review of two
different trimetoprim–sulfamethoxazole regimens used to prevent
Pneumocystis jirovecii and no prophylaxis at all in transplant recipients:
appraising the evidence. Transplant Proc 2009; 41: 1201–1203.
3. Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneu-
mocystis carinii pneumonia in solid organ transplant recipients ever
be discontinued? Clin Infect Dis 1999; 28: 240–246.
4. Lufft V, Kliem V, Behrend M, Pichlmar R, Koch KM, Brunkhorst R.
Incidence of Pneumocystis carinii pneumonia after renal transplanta-
tion: impact of immunosuppression. Transplantation 1996; 62: 421–
423.
5. Arend SM, Westendorp RGJ, Kroon FP et al. Rejection treatment
and CMV infection as risk factors for Pneumocystis carinii pneumonia
in renal transplant recipients. Clin Infect Dis 1996; 22: 920–925.
6. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Anal-
ysis of USRDS: incidence and risk factors for Pneumocystis jirovecii
pneumonia. Transplantation 2009; 88: 135–141.
7. Radisic M, Lattes R, Chapman JF et al. Risk factors for Pneumocystis
carinii pneumonia in kidney transplant recipients: a case–control
study. Transpl Infect Dis 2003; 5: 84–93.
8. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the
immunosuppressant mycophenolate mofetil in contrast to provoca-
tive effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis
1997; 175: 901–904.
9. Schmoldt S, Schuhegger R, Wendler T et al. Molecular evidence of
nosocomial Pneumocystis jirovecii transmission among 16 patients after
kidney transplantation. J Clin Microbiol 2008; 46: 966–971.
10. Hauser PM, Sudre P, Nahimana A, Francioli P, the study group. Pro-
phylaxis failure is associated with a speciﬁc Pneumocystis carinii geno-
type. Clin Infect Dis 2001; 33: 1080–1082.
11. Su YS, Lu JJ, Perng CL, Chang FY. Pneumocystis jirovecii pneumonia in
patients with and without human immunodeﬁciency virus infection.
J Microbiol Immunol Infect 2008; 41: 478–482.
12. De Castro N, Neuville S, Sarfati C et al. Occurrence of Pneumocystis
jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year
retrospective study. Bone Marrow Transplant 2005; 36: 879–883.
13. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel
H. Management and outcome patterns for adult Pneumocystis carinii
pneumonia, 1985 to 1995. Chest 2000; 118: 704–711.
TABLE 2. Univariate and multivariate analyses of risk factors for Pneumocystis jirovecii pneumonia (PCP) among renal trans-
plant recipients
Cases Controls
Univariate analysis Multivariate analysis
OR (95% CI) Mid-p-value OR (95% CI) Mid-p-value
No. of patients 11 22
Male gender, n (%) 7 (64) 15 (68) 0.81 (0.13–5.87) 0.85 – –
Age at transplant (years), mean (SD) 47 (15) 43 (14) 1.03 (0.97–1.12) 0.35 – –
Dialysis duration (years), median (Q1–Q3)
a 5 (4–7) 4 (2–7) 1.12 (0.90–1.44) 0.32 – –
Transplantation number (%)
1 9 (82) 17 (77) 1 Ref. – –
‡2 2 (18) 5 (23) 0.77 (0.07–5.76) 0.84 – –
Induction of immunosuppressive treatment, n (%)
None 0 (0) 1 (5) 1 Ref. – –
ATG 7 (64) 17 (77)
IL-2RA 4 (36) 4 (18) 0.21 (0.004–2.84) 0.20 – –
Transplant rejection episodes, n (%)
0 2 (18) 17 (77) 1 Ref. – –
‡1 9 (82) 5 (23) 14.4 (2.1–Inf) 0.002 8.66 (1.17–Inf) 0.017
Corticosteroids after rejection, n (%) 8 (73) 5 (23) 11.5 (1.66–Inf) 0.004 – –
OKT3 after rejection, n (%) 1 (9) 1 (5) 0.50 (0.01–Inf) 0.67
Maintenance immunosuppressive treatment, n (%)b
Antiproliferative drugs 8 (73) 19 (86) 0.42 (0.03–3.97) 0.52
Calcineurin inhibitors 6 (55) 21 (95) 0.09 (0–0.67) 0.004
mTOR inhibitors 3 (27) 0 (0) 7.70 (1.02–Inf) 0.019
Corticosteroids 9 (82) 16 (73) 2.00 (0.05–Inf) 0.17
Duration of treatment by corticosteroids (months),
>0.25 mg/kg per day, median (Q1–Q3)
3 (2–7) 1.5 (0.3–3) 1.60 (1.04–2.93) per month 0.005
Lymphocyte count <500/lL at prophylaxis discontinuation, n (%) 7 (64) 4 (18) 18.1 (1.66–Inf) 0.0027 5.84 (0.69–Inf) 0.083
History of CMV viraemia 8 (73) 11 (50) 2.63 (0.56–Inf) 0.15
ATG, antithymocyte globulins; CMV, cytomegalovirus; IL-2RA, IL-2 receptor antagonist; Inf, inﬁnity; mTOR, mammalian target of rapamycin; SD, standard deviation.
Associations of variables with PCP are expressed in terms of exact ORs with their 95% CIs. Reported p-values are mid-p-values that adjust for the discreteness of the distri-
bution.
aQ1–Q3, interquartile range.
bPatients received more than one immunosuppressive drug, so the total is more than 100%.
Antiproliferative drugs were mycofenolate mofetil or azathioprine; calcineurin inhibitors were cyclosporine or tacrolimus; mTOR inhibitors were sirolimus or everolimus.
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